ALLK Allakos
- 1.020
- +0.010+0.99%
- 1.070
- +0.050+4.90%
Allakos News
Market Outperform Rating Reiterated for Allakos Amid Promising AK006 Clinical Developments
Hold Rating on Allakos Amidst Cautious Optimism for AK006 Program
Allakos Inc (ALLK) Reports Increased R&D Expenses and Net Loss in Q4
Hold Rating on Allakos Amidst Clinical Pivots and Prospective AK006 Developments
Analysts Are Bullish on These Healthcare Stocks: Allakos (ALLK), Century Therapeutics (IPSC)
Analysts Conflicted on These Healthcare Names: Allogene Therapeutics (ALLO), Aquestive Therapeutics (AQST) and Allakos (ALLK)
TD Cowen Remains a Hold on Allakos (ALLK)
Express News | Allakos Q4 EPS $(0.71) Misses $(0.47) Estimate
Allakos: Ended 4Q With Approximately $170.8 M in Cash, Cash Equivalents and Investments >ALLK
Allakos: Ended 4Q With Approximately $170.8 M in Cash, Cash Equivalents and Investments >ALLK
Allakos: As a Result of the Restructuring Expects Cash Runway to Extend Into Mid-2026 >ALLK
Allakos: As a Result of the Restructuring Expects Cash Runway to Extend Into Mid-2026 >ALLK
Allakos 4Q Loss/Shr 71c >ALLK
Allakos 4Q Loss/Shr 71c >ALLK
Press Release: Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results SAN CARLOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (Nasdaq: ALLK), a
Analysts' Top Healthcare Picks: KalVista Pharmaceuticals (KALV), Allakos (ALLK)
Allakos Reports Potential Skin Inflammation Treatment Progress
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation With AK006 at AAAAI 2024
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an
Allakos Inc Reveals Breakthrough AK006 Data in Allergy Journal
Express News | Allakos Announced The Publication Of New Scientific Results In Allergy. The Preclinical Research Found That AK006 (Agonist Siglec-6 Antibody) Impacts Mast Cell Function By Interacting With Multiple Activating Receptors And Key Signaling Molecules
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition –– AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., Feb.
Allakos Inc. (ALLK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors To...
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
Analysis
Price Target
No Data
